FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-839 in combination with afinitor® (everolimus), for […]

The post FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma appeared first on .